Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
The functional significance of the observed heterogeneity of androgen receptor (AR) expression in prostate cancer is unknown. Here the authors show AR expression heterogeneity is associated with distinct castration/enzalutamide responses and identify BCL-2 as a potential therapeutic target in castra...
Guardado en:
Autores principales: | Qiuhui Li, Qu Deng, Hsueh-Ping Chao, Xin Liu, Yue Lu, Kevin Lin, Bigang Liu, Gregory W. Tang, Dingxiao Zhang, Amanda Tracz, Collene Jeter, Kiera Rycaj, Tammy Calhoun-Davis, Jiaoti Huang, Mark A. Rubin, Himisha Beltran, Jianjun Shen, Gurkamal Chatta, Igor Puzanov, James L. Mohler, Jianmin Wang, Ruizhe Zhao, Jason Kirk, Xin Chen, Dean G. Tang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5a734dbbd52a444ea8aff078384df83d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
LRIG1 is a pleiotropic androgen receptor-regulated feedback tumor suppressor in prostate cancer
por: Qiuhui Li, et al.
Publicado: (2019) -
Author Correction: LRIG1 is a pleiotropic androgen receptor-regulated feedback tumor suppressor in prostate cancer
por: Qiuhui Li, et al.
Publicado: (2020) -
The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer
por: Keliang Wang, et al.
Publicado: (2020) -
Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
por: Ayşe Demirci, et al.
Publicado: (2021) -
Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer.
por: Shunsuke Tsuzuki, et al.
Publicado: (2021)